Assembly Biosciences, Inc. Contract with Customer, Liability, Noncurrent
Assembly Biosciences, Inc. (ASMB) had Contract with Customer, Liability, Noncurrent of $0 as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2026-03-19
- 2025-12-31: Contract with Customer, Liability, Noncurrent $0.00.
- 2025-09-30: Contract with Customer, Liability, Noncurrent $1.72M.
- 2025-06-30: Contract with Customer, Liability, Noncurrent $13.04M.
- 2025-03-31: Contract with Customer, Liability, Noncurrent $22.76M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-19 |
| 2025-09-30 | $1.72M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $13.04M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $22.76M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $35.38M 10-K · filed 2026-03-19 |
| 2024-09-30 | $32.51M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $38.92M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $47.74M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $55.38M 10-K · filed 2025-03-20 |
| 2023-09-30 | $2.73M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $2.73M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $2.73M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $2.73M 10-K · filed 2024-03-28 |
| 2022-09-30 | $2.73M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $2.73M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $2.73M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $2.73M 10-K · filed 2023-03-22 |
| 2021-09-30 | $2.73M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $8.99M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $8.99M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $8.99M 10-K · filed 2022-03-11 |
| 2020-09-30 | $8.99M 10-Q · filed 2020-11-05 |
| 2020-03-31 | $29.33M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $30.64M 10-K · filed 2021-02-25 |
| 2019-09-30 | $32.27M 10-Q · filed 2019-11-07 |
| 2018-12-31 | $35.56M 10-K · filed 2020-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |